
































Age is the major risk factor in the development of many 
chronic medical conditions including cancer [1, 2]. To 
enhance the well-being of an increasingly aged 
population, and to identify new avenues for therapeutic 
intervention, it is crucial that we understand the 
molecular basis underlying aging and age-related 
diseases. Aging can be defined as the “progressive 
deterioration of virtually every bodily function over 
time” [3] ultimately resulting in death. At the cellular 
level, aging is associated with an increase in DNA 
lesions, together, with defects in DNA repair 
mechanisms. Of particular relevance is DNA damage 
associated with critically shortened telomeres. 
Telomeres, which cap the ends of chromosomes, consist 
of hexameric TTAGGG repeats and the protective 
“shelterin” protein complex [4]. Due to the “end 
replication problem”, telomeres shorten during each 
replication cycle and critically shortened telomeres 
elicit a persistent DNA damage response that triggers an 
irreversible   growth   arrest   (senescence).    Shortened  
 
 































telomeres limit the regenerative capacity of tissues and 
are associated with increased age and a variety of 
medical conditions including Dykeratosis Congenita, 
aplastic anemia, and pulmonary fibrosis [5, 6]. In germ 
cells, stem cells and ~85% of cancers, telomere length is 
maintained by telomerase, a ribonucleoprotein 
consisting of a reverse transcriptase (TERT) and its 
RNA moiety (TERC); expression of telomerase renders 
cells immortal.  
 
Two segmental premature aging diseases that clinically 
appear to present as accelerated aging in some tissues, 
are Werner syndrome and Hutchinson-Gilford Progeria 
(HGPS). In both diseases recent evidence indicates that 
mutations in the genes responsible for these premature 
aging diseases result in increased DNA damage, 
particularly at telomeres. Although shortening and/or 
damage to telomeres is associated with proliferative 
arrest of cells in vitro, it remains unclear how accurately 
these diseases recapitulate the processes of tissue aging 
in humans. Here we discuss recent advances, using in 



















physiological  human  aging?  Much  of  what  we  know  stems  from  the  study  of  patient  derived  fibroblasts  with  both
mutations resulting in increased DNA damage, primarily at telomeres. However, in vivo patients with Werner’s develop
arteriosclerosis, among other pathologies. In HGPS patients, including iPS derived cells from HGPS patients, as well as some
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A) what is the molecular mechanism of how such 
seemingly unrelated proteins cause similar degenerative 
diseases? B) are these mechanisms representative of 
normal aging? 
 
Werner Syndrome and Hutchinson-Gilford Progeria  
 
Werner syndrome is caused by mutations in the Werner 
RecQ helicase, a DNA helicase/exonuclease [7] 
whereas HGPS is caused by mutations in Lamin A 
(LMNA) [8, 9].  The Wrn RecQ helicase is involved in 
repair of double strand DNA breaks and in faithful 
replication of lagging-strand telomeres. In its mutated 
form, WRN causes sporadic loss of telomeres generated 
by lagging strand synthesis, increased DNA damage 
(presumably caused by critically shortened telomere(s)), 
premature senescence and genomic instability [10, 11]. 
These phenotypes are suppressed in the presence of 
telomerase [10, 12, 13]. In Werner syndrome, telomere 
dysfunction is causal to the accumulation of DNA 
damage foci and results in premature senescence in 
vitro. These defects may, therefore, underlie the in vivo 
disease etiology.   
 
The A-type lamins are nuclear intermediate filament 
proteins that form the nuclear lamina. The lamina 
underlies the inner nuclear membrane (INM) and is 
important in maintaining interphase nuclear shape, 
mechanical integrity and also functions as a scaffold for 
other nuclear proteins, some of which regulate DNA 
replication and transcription.  The most intriguing aspect 
of the lamins, particularly LaminA, is that some dozen or 
so diseases, the laminopathies, are caused by different 
mutations in the Lmna gene. These diseases affect tissues 
primarily of mesenchymal origin, resulting in defective 
muscle and cardiac function, fat deposition, skeletal 
homeostasis and vascular integrity [14]. 
 
A critical feature of LaminA is that the protein 
undergoes significant post-translational processing. The 
processing involves farnesylation of the C-terminal 
cysteine, which is thought to promote the association of 
the LaminA protein with the INM. The farnesylated 
LaminA protein then undergoes two proteolytic 
cleavage steps, by the endoprotease ZMPSTE24, 
culminating in the removal of the farnesyl group and the 
18 C-terminal amino acids. In HGPS, the most common 
cause is a point mutation in the LMNA gene, which 
creates a novel splice site, removing 50 amino acids 
from the C-terminal globular domain. The deletion 
includes the ZMPSTE24 endoproteolytic site, resulting 
in the synthesis of a truncated, farnesylated form of 
LaminA, called Progerin [8, 9]. To what extent the 
deletion and/or the persistent farnesylation is the 
molecular basis to HGPS is unclear, as a mouse model 
of HGPS expressing the truncated, but non-farnesylated 
variant of Progerin still develop progeroid symptoms 
[15] and non farnesylated Progerin in human cells 
elicits the same DNA damage responses as farnesylated 
Progerin [16].  In addition, other patients, diagnosed 
with Progeria or, intriguingly with atypical Werner’s 
syndrome, have mis-sense mutations elsewhere in the 
Lmna gene and it seems unlikely that these mutations 
affect endoproteolytic cleavage or farnesyl processing, 
although this needs to be confirmed [17]. Progerin 
results in abnormal nuclear morphologies, altered 
chromatin organization, delayed mitosis, lamina 
thickening, and growth arrest [18-20].  However 
increasing evidence suggests that at least one 
underlying cause is that Progerin damages telomeres.  
First, and in parallel with their limited proliferative 
capacity, progeric fibroblasts have significantly shorter 
telomeres than age-matched controls [21, 22]. Secondly, 
expressing Progerin in wild-type fibroblasts gradually 
inhibits their proliferation.  Strikingly, proliferative 
inhibition is reversed by telomerase activation and to 
some extent by p53-deficiency [23], suggesting that 
Progerin directly or indirectly damages telomeres, thus 
activating p53, but the damage is reversed by 
telomerase.  Thirdly, persistent activation of DNA 
damage checkpoints and increased numbers of DNA 
damage foci are present in HGPS-patient derived 
fibroblasts [16, 24, 25]. Increased DNA damage is a 
classic feature of cells undergoing senescence due to 
shortened or deprotected telomeres [26, 27].  The DNA 
damage foci co-localize with human TRF1, a 
component of the shelterin complex, and the DNA 
damage sensor H2A-X is also expressed and enriched at 
telomeric DNA [28].  In addition, live cell imaging and 
cytometric analysis indicate that telomeres in Progeria 
patient-derived cells are hypermobile [29], a 
characteristic of de-protected telomeres [30]. Lastly, 
many of these Progerin induced defects, are suppressed 
by expression of telomerase in fibroblasts [23, 28]. 
 
Together, increased DNA damage, as well as the 
shortened telomeres in HGPS, are considered as 
characteristics of normal human aging. However a 
significant difference is that during normal aging, 
telomere dysfunction is mainly a consequence of the 
end replication problem, which may also be enhanced 
by DNA damaging agents such as oxidative stress [31].  
In HGPS, telomeres may be directly damaged by 
Progerin.  However, the precise mechanism by which 
telomeres are damaged, and whether only a subset of 
telomeres, such as those located at the nuclear 
periphery, still needs to be established. How well do 
these in vitro cell culture results recapitulate the in vivo 
pathologies in patients and mouse models of Progeria? 
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The role of DNA damage resulting in accelerated aging 
has been recapitulated in a number of mouse models 
(reviewed by Schumacher et al. [32]). One example is 
the XPF-ERCC1-deficient mouse. XPF-ERCC1 is 
required for nucleotide excision repair, and repairs 
DNA lesions due to UV radiation. XPF-ERCC1-
deficient mice exhibit slightly retarded embryonic and 
post-natal development, followed by growth arrest by 
~2 weeks, and death at ~4 weeks after birth.   
Phenotypically, these mice show aged-like phenotypes 
in skin, liver and bone marrow. XPF-ERCC1 cells 
prematurely senesce and are more sensitive to oxidative 
stress [33]. Two mouse models for Werner syndrome 
were generated by deletion of the Wrn gene, but neither 
recapitulated any accelerated aging phenotypes 
observed in humans or in cultured cells [34, 35]. This 
discrepancy was thought to be due to laboratory mice 
having extremely long telomeres and residual levels of 
telomerase in some somatic tissues [36, 37]. 
Accordingly, the additional deletion of terc (the RNA 
component of telomerase)  in  Wrn mice resulted in 
shortened telomeres, with the appearance of the classic 
phenotypes of accelerated aging, i.e. grey hair, 
osteoporosis, alopecia and premature death [38]. 
Embryonic fibroblasts (MEFs) from these mice 
exhibited genomic instability, increased levels of DNA 
damage and senesced prematurely, corroborating 
previous results [38].  Interestingly, in contrast to 
telomerase-deficient mice, in which the degenerative 
phenotypes manifest mainly in highly proliferative 
tissues (intestine, skin and blood), in Wrn
-/-/Terc
-/- mice, 
tissues of mesenchymal origin were mainly affected 
resulting in osteoporosis, cataracts and diabetes [38].  
 
Several HGPS-progeroid mouse models have been 
established to investigate how Lmna mutations, 
including defective processing of normal Lamin A, may 
accelerate aging [39-45].  The first Lmna mutant 
showing premature aging was generated by a splicing 
defect deleting exon 9, resulting in an in frame deletion 
of 40 amino acids in the C-terminal domain 
(Lmna
L530P/L530P; also called ∆9Lmna) [39]. The 
mutation, like Progerin, results in a truncated variant of 
LaminA that remains farnesylated, although the ∆9 
protein is expressed at about 10% that of wild-type 
levels.  At birth, homozygotes were indistinguishable 
from their wild-type littermates. However, post-nataly, 
they exhibit a rapid onset of severe growth retardation, 
loss of subcutaneous fat, poor heart development, 
skeletal abnormalities, decreased hair follicle density, 
culminating in death at 3-4 weeks. Postnatal ∆9Lmna 
fibroblasts (MAFs), established from several different 
tissues, show a highly restricted proliferative capability 
with early death. Although ∆9Lmna MAFs do exhibit 
abnormal nuclear morphologies, premature death of the 
cells was not associated with overt chromosomal 
defects such as aneuploidy or increased DNA damage.  
Loss of the MAFs proliferative capability was due to 
reduced synthesis of some 30 extracellular matrix 
proteins (ECM), since serial culture of the ∆9Lmna 
fibroblasts on ECM deposited by normal MAFs 
sustained their proliferation.  Surprisingly, and in 
contrast to the MAFs, the growth properties of ∆9Lmna 
embryonic fibroblasts (MEFs) were practically 
indistinguishable from their wild type counterparts, 
despite having defective nuclear morphologies, and 
identical ∆9Lmna expression levels to MAFs [45].  
 
These findings revealed an unexpected difference 
between embryonic and post-natal fibroblasts in their 
susceptibility to ∆9Lmna, suggesting a possible 
explanation as to why progeric children are overtly 
normal at birth, since A-type lamins (and probably 
Progerin) are expressed during development [46-48]. 
One significant molecular difference between MEFs 
and MAFs is that MAFs express higher levels of the 
Wnt regulated transcription factor Lef1, compared to 
MEFs. Similar differences in LEF1 levels were also 
noted in normal human fibroblasts with 12-16 week old 
fetal fibroblasts expressing reduced levels of LEF1 
compared to those from a 17-year old individual 
(unpublished observations).  In the ∆9Lmna MAFs Lef1 
levels were markedly reduced, due to ∆9Lmna 
inhibition of canonical Wnt signaling.  LEF1 levels 
were also significantly reduced in fibroblasts 
established from two HGPS children, indicating that 
different truncated, farnesylated LMNA mutant proteins 
inhibit LEF1 expression and function.  Some of the 
ECM genes, whose expression was reduced by 
∆9Lmna,  are transcriptionally regulated by Lef1 
indicating a direct link between the inhibition of ECM 
gene expression and ∆9Lmna.  The finding that ECM 
expression was significantly reduced in the ∆9Lmna 
model was similar to microarray studies on HGPS 
fibroblasts and MSCs, where ECM gene expression was 
also profoundly altered [48-50]. 
 
Loss of the endoprotease ZMPSTE24 results in the 
persistence of unprocessed, farnesylated, full length pre-
laminA.  Mice lacking ZMPSTE24 develop progeroid 
features which include skeletal abnormalities, alopecia 
and death by 6 months, [24, 41, 43].  In contrast to 
mice, the few humans identified with ZMPSTE24 
deficiency, develop restrictive dermopathy (RD) or tight 
skin, resulting in perinatal mortality [51].  Cells, 
including MEFs, from Zmpste24 null mice show 
increased cellular DNA damage, together with defective 
DNA damage responses, as well as defective Wnt 
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aging phenotype of Zmpste24
-/- mouse was partly 
alleviated when crossed into a p53-deficient background 
[40] and completely rescued when made heterozygous 
for Lmna expression revealing a dosage effect of pre-
laminA on the pathology [40]. Analysis of fibroblasts 
from one patient with RD also revealed persistent 
activation of DNA damage checkpoints [16]. Why 
ZMPSTE24 loss in humans results in a more severe 
(peri-natal) pathology than in mice is unclear, although 
it is possible that mice may be more “resistant” to 
Zmpste24 deficiency because of their longer telomeres. 
These results reflect the in vitro results reported by 
Kudlow et al., and others [23, 28] in which inhibition of 
p53 signaling rescued the Progerin-induced DNA 
damage and impaired proliferation. However, it is still 
unclear whether Zmpste24-deficiency damages 
telomeres in a similar way to Progerin.  
   
In other progeroid mouse lines, Lmna was replaced with 
a variant allele that only expresses Progerin (Lmna
HG/+). 
At birth these mice were overtly normal with the 
Lmna
HG/+  heterozygotes  showing retarded postnatal 
growth, weight loss, diminished adipose tissue, skeletal 
defects and death by nine months [53]. The few 
homozygotes produced, showed severe growth 
retardation and all died by three weeks.  In contrast to 
Zmpste24
–/– mice, skeletal muscle function was 
unaffected and, as with the ∆9Lmna mice, no pathology 
was detected in the ascending aorta, although the state 
of the great vessels was not reported. It is noteworthy 
that all three mouse lines show similar pathologies in 
mesenchymal tissues, with the skeletal system, being 
predominantly affected. 
 
In addition to these three lines where the indigenous 
Lmna gene was modified, transgenic lines were derived 
in which Progerin was expressed as a transgene. In two 
of the transgenic lines Progerin was specifically 
expressed in the skin and resulted in abnormal nuclear 
morphologies and in one line, epidermal hyperplasia, 
hyperparakeratosis, hyperplasia of the sebaceous 
glands, culminating subcutaneous fat loss, dermal 
fibrosis and hypoplastic sebaceous glands and dental 
defects [54, 55]. In the third line, no overt effect was 
noted, however, by one year, loss of vascular smooth 
muscle was detected in the aorta [42].  
 
How do these findings explain that HGPS patients die 
in their early to mid teens from atherosclerosis and does 
this relate to normal aging? Post-mortem analyses of a 
few HGPS patients revealed extensive loss of vascular 
smooth muscle (VSM), particularly in the aorta and 
great vessels proximal to the heart and, in two others, 
extensive atherosclerosis [56, 57]. In two progeroid 
mouse models, extensive loss of VSM in both the aorta 
and great vessels proximal to the heart was present. In 
the ∆9Lmna mutant mice, a rapid onset of VSM loss, 
together with increased apoptosis in the great vessels 
proximal to the heart was apparent at 2 weeks of age. 
These mice also exhibited extensive reduction in many 
ECM genes expressed in the skeletal system together 
with reduced trabecularity and minerality in the 
calvarial and axial skeleton, features consistent with the 
skeletal pathology found in HGPS. In the transgenic 
model [42], the human Progerin transgene resulted in 
loss of VSM in the aorta, but only after one year.   
Similarly, Werner’s patients show accelerated 
atherosclerosis and death from myocardial infarction, 
despite normal circulating cholesterol levels. This 
suggests that cardiovascular defects are frequently 
associated with increased DNA damage and/or that the 
cardiovascular system is particularly sensitive or 
susceptible to DNA damage [58].  
 
The ∆9Lmna mutant phenocopies many of the tissue, 
cellular and molecular pathologies characteristic of 
Progeria, yet, a number of interesting discrepancies 
exist.  How does the ∆9Lmna mutation lead to 
decreased Wnt-signaling, and does this, in turn, 
exclusively reduce ECM synthesis? Progerin inhibits 
Wnt signaling to a lesser extent than the ∆9Lmna 
mutant, although progeric fibroblasts show reduced 
levels of Lef1 and treatment with a GSK-3 inhibitor 
improves their proliferation [45].  Moreover, what is the 
role of DNA damage in the ∆9Lmna mice since there 
was no evidence of increased genomic instability or an 
increase in H2A-X foci?  If so, how, and to what extent 
could wild type ECM restore this phenotype?  Are the 
farnesylated, truncated variants of LaminA, defective in 
Wnt signaling, telomere damage and disrupted ECM 
expression somehow interlinked? Some (or all?) of 
these parameters are clearly affected during normal 
ageing, but why are they especially critical to the 
vascular system? One common link maybe through the 
Forkhead box O (FoxO) transcription factor network. 
Oxidative stress activates these factors, which in turn 
inhibit Wnt mediated transcription by competing for β-
catenin. Inhibition of FOXO mediated transcription 
factor activity improves VSM viability and promotes 
osteoblast differentiation [59].  
 
Differences in telomere length and maintenance between 
mice and humans are an important consideration when 
generating mouse models for Werner syndrome and 
Ataxia telangectasia; in both cases Wrn-/- and Atm-/- 
deficient mice exhibited progeriod features only after 
they were crossed into a telomerase-deficient background 
[38, 60]. However the role of DNA damage in the 
molecular pathology of HGPS remains open. Mouse 
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develop a progeroid phenotype. Furthermore, other 
progeroid/atypical Werner’s cases, caused by LMNA 
mutations, have not been investigated as to whether these 
mutations result in DNA damage.  
 
HGPS is complex, although some understanding of the 
molecular pathology has been gained by the study of 
patient-derived fibroblasts, ectopically expressed 
proteins in normal human fibroblasts and mouse 
models. Nevertheless, we still lack a clear picture how 
(and if) Progerin, Wnt signaling, the ECM, DNA 
damage and telomeres are interconnected. Two recently 
generated  in vitro disease models for Progeria using 
induced pluripotent stem cells (iPSC) provide further 
insights [48, 61]. iPSC do not express Lamin A (or 
Progerin), are overtly normal, and can differentiate into 
relevant tissues that are particularly affected in Progeria 
patients (i.e. mesenchymal lineages, vascular smooth 
muscle etc), and which cannot be derived from patients. 
From such “disease in a dish” studies it was apparent 
that VSM and mesenchymal stem cells were especially 
sensitive to Progerin, possibly because they expressed 
the highest levels of Progerin-LaminA, relative to other 
cell types, such as endothelial and neuronal lineages. It 
was noted that the HGPS-MSCs showed elevated levels 
of DNA damage and were far less efficient than normal 
MSCs at rescuing vascular circulation following 
ischemia [46]. In addition, comparison of gene 
expression profiles between MSCs derived from normal 
individuals and HGPS-MSCs, it was striking that Gene 
Ontology analysis revealed both Extracellular Matrix 
and Wnt signaling to be the most significant differences 
between the HGPS- and normal MSCs [48].  
 
However the recurring question is do progeric diseases 
tell us something about the normal ageing process?  In a 
recent study, VSM isolated from arteries from a limited 
number of 70-80 year old individuals, expressed 
elevated levels of pre-laminA, the farnesylated 
precursor of mature LaminA, whereas in the arteries 
from teenagers no pre-lamin A was detected [62]. This 
increase of pre-laminA was due to decreased levels of 
ZMPSTE24 in the VSM, possibly as a consequence of 
ZMPSTE24 expression being sensitive to oxidative 
stress. VSM cells appear to be particularly vulnerable to 
the anti-proliferative effects of pre-laminA, as 
suggested by VSM derived from HGPS iPS cells [48].  
Why VSM should be seemingly sensitive to Progerin is 
unclear, but it maybe relevant that in skin biopsies from 
HGPS patients, VSM expressed the highest levels of 
Progerin [18, 48]. Several studies have also suggested 
that low levels of Progerin protein may be detected in 
tissues from aged individuals [62, 63].  It is conceivable 
that part of the normal aging process, is a decline in 
vascular integrity due to defective LaminA processing.  
Defective processing may arise either due to a decrease 
in ZMPSTE24 activity and/or defective splicing 
resulting in low but significant levels of Progerin being 
produced [63].  In addition, it remains to be established 
to what extent the other tissue pathologies in HGPS, 
arise either through autonomous cell expression of 
Progerin or are a consequence of the vascular defects.  
These issues and whether defective LaminA processing 
enhances telomeric DNA damage, inhibits Wnt 
signaling and ECM regulation, all of which may 
contribute to the normal process of aging, are all 
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